Edition:
United Kingdom

Granules India Ltd (GRAN.NS)

GRAN.NS on National Stock Exchange of India

102.45INR
9:59am GMT
Change (% chg)

Rs1.70 (+1.69%)
Prev Close
Rs100.75
Open
Rs101.45
Day's High
Rs102.70
Day's Low
Rs100.40
Volume
1,276,638
Avg. Vol
4,642,719
52-wk High
Rs150.00
52-wk Low
Rs71.55

Latest Key Developments (Source: Significant Developments)

India's Granules India Sept-Qtr Consol Profit Rises
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Granules India Ltd ::SEPT QUARTER CONSOL PROFIT 602.6 MILLION RUPEES VERSUS PROFIT 403.3 MILLION RUPEES YEAR AGO.SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 5.81 BILLION RUPEES VERSUS 3.93 BILLION RUPEES YEAR AGO.DECLARED INTERIM DIVIDEND OF 0.25 RUPEES PER SHARE.  Full Article

Granules India Unit Completes FDA Inspection With Two Form 483 Observations
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Granules India Ltd ::SAYS GRANULES PHARMACEUTICALS INC. COMPLETED U.S. FDA INSPECTION.SAYS INSPECTION COMPLETED WITH TWO FORM 483 OBSERVATIONS.  Full Article

India's Granules India June Qtr Consol Net Profit Rises
Monday, 23 Jul 2018 

July 23 (Reuters) - Granules India Ltd ::JUNE QUARTER CONSOL NET PROFIT 518.0 MILLION RUPEES VERSUS 368 MILLION RUPEES YEAR AGO.JUNE QUARTER CONSOL REVENUE FROM OPERATIONS 4.53 BILLION RUPEES VERSUS 3.85 BILLION RUPEES YEAR AGO.DECLARED INTERIM DIVIDEND OF 0.25 RUPEES PER SHARE.  Full Article

Granules India Gets EIR From U.S. FDA For Gagillapur Facility In Hyderabad
Friday, 1 Jun 2018 

June 1 (Reuters) - Granules India Ltd ::SAYS US FDA ISSUED EIR (ESTABLISHMENT INSPECTION REPORT) FOR CO'S GAGILLAPUR FACILITY IN HYDERABAD.SAYS NO 483 OBSERVATIONS GIVEN DURING INSPECTION BY FDA.  Full Article

Granules India March-Qtr Consol Profit More Than Halves
Thursday, 24 May 2018 

May 24 (Reuters) - Granules India Ltd ::MARCH QUARTER CONSOL NET PROFIT 204.4 MILLION RUPEES VERSUS PROFIT 456.7 MILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 5.04 BILLION RUPEES VERSUS 3.62 BILLION RUPEES YEAR AGO.RECOMMENDED DIVIDEND OF 0.25 RUPEES PER SHARE.  Full Article

Granules India Gets EIR From U.S. FDA For Co's Jeedimetla Facility In Hyderabad
Wednesday, 16 May 2018 

May 16 (Reuters) - Granules India Ltd ::SAYS USFDA ISSUED ESTABLISHMENT INSPECTION REPORT FOR CO'S JEEDIMETLA FACILITY IN HYDERABAD.SAYS CO'S JEEDIMETLA FACILITY MANUFACTURES ACTIVE PHARMACEUTICAL INGREDIENTS AND PHARMACEUTICAL FORMULATION INTERMEDIATES.  Full Article

Granules India Gets ANDA Nod For Methocarbamol Tablet
Tuesday, 8 May 2018 

May 8 (Reuters) - Granules India Ltd ::SAYS CO GETS ANDA NOD FOR METHOCARBAMOL TABLET.SAYS CO EXPECTS TO COMMERCIALIZE PRODUCT SHORTLY.  Full Article

Granules India Gets One Form 483 Observation For Jeedimeetla Facility
Monday, 26 Mar 2018 

March 26 (Reuters) - Granules India Ltd ::GAGILLAPUR, JEEDIMETLA FACILITIES COMPLETED U.S. FDA INSPECTION; NO 483 OBSERVATION FOR GAGILLAPUR; 1 OBSERVATION FOR JEEDIMEETLA.  Full Article

Granules India's Virginia Unit Completes U.S. FDA Audit With 1 Observation
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Granules India Ltd ::SAYS GRANULES PHARMACEUTICALS COMPLETES U.S. FDA INSPECTION WITH 1 OBSERVATION.  Full Article

Granules India Sept-qtr consol profit falls
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Granules India Ltd :Sept quarter consol net profit 403.4 million rupees versus profit 408.2 million rupees year ago.Sept quarter consol revenue from operations 3.93 billion rupees versus 3.64 billion rupees year ago.Declared dividend of 0.25 rupees per share.  Full Article